{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The amount of participants that survive one year after treatment with BBd and do not experience worsening disease.","groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.\n\nBendamustine hydrochloride: Given IV\n\nBortezomib: Given SC\n\nDexamethasone: Given PO","id":"OG000","title":"Bendamustine, Bortezomib, Dexamethasone (Standard)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"4 were not evaluable - (1 didn't get any therapy on study, 1 received only first cycle and 2 developed medical issues that took them off study during the first cycle)","reportingStatus":"POSTED","timeFrame":"1 year","title":"Count of Participants That Experience Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Participants"}